Part B

The Comprehensive Error Rate Testing (CERT) A/B MAC Outreach & Education Task Force, a collaboration of all Part A and Part B MACs, has published a presentation providing you with an overview of…

Medicare will pay for Kisunla for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. Please review this article and pay close attention to the billing…

Botulinum toxins are potent neuromuscular blocking agents that are useful in treating various focal muscle spastic disorders and excessive muscle contractions, such as dystonia, spasms, and twitches.

CMS recently revised the code descriptor for HCPCS code G0136 to remove the social determinants of health risk (SDOH) assessment. The code remains on the Medicare telehealth services list. View this…

Read this article for important changes and revisions to the MDPP program for calendar year 2026.

CMS implemented a prior authorization program for certain hospital outpatient department services for dates of service on or after July 1, 2020.

CMS implemented a prior authorization program for certain hospital outpatient department services for dates of service on or after July 1, 2020.

Effective April 1, the MPFS will reflect updated pricing for a number of codes. Please review this article to learn about which codes are affected and the new amounts.

Vein ablation and related services; some patients may want varicose vein treatment for cosmetic reasons. Medicare does not cover cosmetic surgery or expenses incurred in connection with such surgery.

Botulinum toxins are potent neuromuscular blocking agents that are useful in treating various focal muscle spastic disorders and excessive muscle contractions, such as dystonia, spasms, and twitches.